Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$9.84 USD

9.84
1,476,002

+0.08 (0.82%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $9.84 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Adma Biologics (ADMA) Outpaced the Stock Market Today

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $18.34, indicating a +1.72% shift from the previous trading day.

Zacks Equity Research

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Artivion (AORT) have performed compared to their sector so far this year.

Zacks Equity Research

Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know

by Zacks Equity Research

ZTS faces steep YTD losses as safety concerns hit key osteoarthritis therapies, forcing revenue cuts while new approvals aim to stabilize growth.

Zacks Equity Research

PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain

by Zacks Equity Research

Pacira BioSciences' iovera shows stronger, longer-lasting relief than RFA in a pilot CLBP study, highlighting its tissue-sparing approach and potential spine-care impact.

Zacks Equity Research

AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension

by Zacks Equity Research

AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.

Zacks Equity Research

MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study

by Zacks Equity Research

Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.

Zacks Equity Research

JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis

by Zacks Equity Research

J&J gains EU approval for Imaavy, the first FcRn blocker for adults and adolescents with generalized myasthenia gravis.

Zacks Equity Research

ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know

by Zacks Equity Research

Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.

Zacks Equity Research

Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet

by Zacks Equity Research

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?